Logo image of RVMD

REVOLUTION MEDICINES INC (RVMD) Stock Fundamental Analysis

NASDAQ:RVMD - Nasdaq - US76155X1000 - Common Stock - Currency: USD

40.99  -0.15 (-0.36%)

After market: 40.99 0 (0%)

Fundamental Rating

3

RVMD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RVMD as it has an excellent financial health rating, but there are worries on the profitability. RVMD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RVMD had negative earnings in the past year.
In the past year RVMD has reported a negative cash flow from operations.
RVMD had negative earnings in each of the past 5 years.
In the past 5 years RVMD always reported negative operating cash flow.
RVMD Yearly Net Income VS EBIT VS OCF VS FCFRVMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M -400M

1.2 Ratios

RVMD has a better Return On Assets (-32.16%) than 64.96% of its industry peers.
The Return On Equity of RVMD (-36.20%) is better than 74.69% of its industry peers.
Industry RankSector Rank
ROA -32.16%
ROE -36.2%
ROIC N/A
ROA(3y)-25.72%
ROA(5y)-24.94%
ROE(3y)-30.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
RVMD Yearly ROA, ROE, ROICRVMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

RVMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVMD Yearly Profit, Operating, Gross MarginsRVMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RVMD has been increased compared to 1 year ago.
Compared to 5 years ago, RVMD has more shares outstanding
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RVMD Yearly Shares OutstandingRVMD Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
RVMD Yearly Total Debt VS Total AssetsRVMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

RVMD has an Altman-Z score of 21.68. This indicates that RVMD is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 21.68, RVMD belongs to the best of the industry, outperforming 93.63% of the companies in the same industry.
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.68
ROIC/WACCN/A
WACC11.16%
RVMD Yearly LT Debt VS Equity VS FCFRVMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 500M 1B 1.5B

2.3 Liquidity

RVMD has a Current Ratio of 14.24. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RVMD (14.24) is better than 88.50% of its industry peers.
RVMD has a Quick Ratio of 14.24. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 14.24, RVMD belongs to the best of the industry, outperforming 88.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.24
Quick Ratio 14.24
RVMD Yearly Current Assets VS Current LiabilitesRVMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for RVMD have decreased strongly by -10.02% in the last year.
Looking at the last year, RVMD shows a very negative growth in Revenue. The Revenue has decreased by -97.16% in the last year.
Measured over the past years, RVMD shows a very negative growth in Revenue. The Revenue has been decreasing by -10.50% on average per year.
EPS 1Y (TTM)-10.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.34%
Revenue 1Y (TTM)-97.16%
Revenue growth 3Y-35.41%
Revenue growth 5Y-10.5%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RVMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.29% on average per year.
RVMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.21% yearly.
EPS Next Y5.94%
EPS Next 2Y-3.31%
EPS Next 3Y-3.81%
EPS Next 5Y12.29%
Revenue Next Year-97.31%
Revenue Next 2Y-27.45%
Revenue Next 3Y19.52%
Revenue Next 5Y123.21%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RVMD Yearly Revenue VS EstimatesRVMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
RVMD Yearly EPS VS EstimatesRVMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RVMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RVMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVMD Price Earnings VS Forward Price EarningsRVMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVMD Per share dataRVMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as RVMD's earnings are expected to decrease with -3.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.31%
EPS Next 3Y-3.81%

More info and screens

0

5. Dividend

5.1 Amount

RVMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVOLUTION MEDICINES INC

NASDAQ:RVMD (1/24/2025, 5:56:19 PM)

After market: 40.99 0 (0%)

40.99

-0.15 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners103.07%
Inst Owner Change0.01%
Ins Owners2.09%
Ins Owner Change0.21%
Market Cap7.56B
Analysts88.57
Price Target74.46 (81.65%)
Short Float %9.06%
Short Ratio9.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.83%
Min EPS beat(2)-3.17%
Max EPS beat(2)-2.48%
EPS beat(4)1
Avg EPS beat(4)-6.08%
Min EPS beat(4)-26.7%
Max EPS beat(4)8.02%
EPS beat(8)4
Avg EPS beat(8)0.93%
EPS beat(12)6
Avg EPS beat(12)0.32%
EPS beat(16)7
Avg EPS beat(16)-2.87%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-83.33%
Min Revenue beat(4)-100%
Max Revenue beat(4)-33.33%
Revenue beat(8)3
Avg Revenue beat(8)-8.18%
Revenue beat(12)5
Avg Revenue beat(12)-7.85%
Revenue beat(16)6
Avg Revenue beat(16)-14.67%
PT rev (1m)2.2%
PT rev (3m)22.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-79.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-78.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10182.31
P/FCF N/A
P/OCF N/A
P/B 4.82
P/tB 5.05
EV/EBITDA N/A
EPS(TTM)-3.59
EYN/A
EPS(NY)-4.03
Fwd EYN/A
FCF(TTM)-2.99
FCFYN/A
OCF(TTM)-2.93
OCFYN/A
SpS0
BVpS8.5
TBVpS8.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.16%
ROE -36.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.72%
ROA(5y)-24.94%
ROE(3y)-30.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.62%
Cap/Sales 1537.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.24
Quick Ratio 14.24
Altman-Z 21.68
F-Score4
WACC11.16%
ROIC/WACCN/A
Cap/Depr(3y)166.18%
Cap/Depr(5y)131.14%
Cap/Sales(3y)39.85%
Cap/Sales(5y)26.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.34%
EPS Next Y5.94%
EPS Next 2Y-3.31%
EPS Next 3Y-3.81%
EPS Next 5Y12.29%
Revenue 1Y (TTM)-97.16%
Revenue growth 3Y-35.41%
Revenue growth 5Y-10.5%
Sales Q2Q%N/A
Revenue Next Year-97.31%
Revenue Next 2Y-27.45%
Revenue Next 3Y19.52%
Revenue Next 5Y123.21%
EBIT growth 1Y-77.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.58%
EBIT Next 3Y-23.76%
EBIT Next 5Y-2.34%
FCF growth 1Y-161.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-167.35%
OCF growth 3YN/A
OCF growth 5YN/A